Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

5,224

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Gastric CancerHelicobacter Pylori Infection
Interventions
DRUG

10-day bismuth-based quadruple therapy

Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days

OTHER

Placebo

Placebo for bismuth-based quadruple therapy

Trial Locations (11)

21431

Incheon St.Mary's Hospital/The Catholic University, Incheon

24253

Hallym University Chuncheon Sacred Heart Hospital, Chuncheon

49267

Kosin University Gospel Hospital, Busan

620-739

Pusan National University Hospital, Busan

702-911

Kyungpook National University Hospital, Daegu

410-769

National Cancer Center, Goyang

501-757

Chonnam National University Hospital, Gwangju

05355

Kandong Sacred Heart Hospital, Seoul

07061

SMG-SNU Boramae Medical Center, Seoul

156-861

Chung-Ang University Hospital, Seoul

480-821

Uijeongbu St. Mary's Hospital/The Catholic University, Uijeongbu-si

All Listed Sponsors
collaborator

International Agency for Research on Cancer

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Uijeongbu St. Mary's Hospital/The Catholic University

UNKNOWN

collaborator

Kangdong Sacred Heart Hospital

OTHER

collaborator

Incheon St.Mary's Hospital/The Catholic University

UNKNOWN

collaborator

SMG-SNU Boramae Medical Center

OTHER

collaborator

Chuncheon Sacred Heart Hospital

OTHER

collaborator

Kosin University Gospel Hospital

OTHER

lead

National Cancer Center, Korea

OTHER_GOV